

CYFARFOD BWRDD PRIFYSGOL IECHYD UNIVERSITY HEALTH BOARD MEETING

DYDDIAD Y CYFARFOD: DATE OF MEETING:	30 September 2021
TEITL YR ADRODDIAD: TITLE OF REPORT:	Hywel Dda University Health Board Pharmaceutical Needs Assessment – October 2021
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Jill Paterson - Director of Primary Care, Community and Long Term Care
SWYDDOG ADRODD: REPORTING OFFICER:	Jenny Pugh-Jones - Clinical Director of Pharmacy and Medicines Management

Pwrpas yr Adroddiad (dewiswch fel yn addas) Purpose of the Report (select as appropriate) Ar Gyfer Penderfyniad/For Decision

ADRODDIAD SCAA SBAR REPORT <u>Sefyllfa / Situation</u>

Heath Boards in Wales are required by section 82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020, to publish a Pharmaceutical Needs Assessment (PNA) by the 1st October 2021.

In response to this statutory duty, the Health Board has gathered intelligence from a range of sources to prepare the Hywel Dda University Health Board Pharmaceutical Needs Assessment - October 2021. This document, which has been subject to a public consultation, includes data and feedback from patient and contractor surveys, Public Health Wales and information on existing commissioned services from Community Pharmacy.

The Hywel Dda UHB Pharmaceutical Needs Assessment:

- Sets out the current health needs of the population and how they will change over the five-year lifetime of the document (1 October 2021 to 30 September 2026)
- Describes the current provision of pharmaceutical services by pharmacies, dispensing appliance contractors and dispensing doctors both within and outside of the health board's area
- Takes into account known changes that will arise during the lifetime of the document such as demographic changes, housing developments, regeneration projects, and changes to the location of other NHS service providers, and
- Identifies any current gaps in service provision and any that will arise during the lifetime of the document

While there remains opportunities for the Health Board to continue working with Community Pharmacy to further improve access to enhanced services, the outcome of the Health Board's PNA has identified there are no current gaps in the current provision of services.

The Board is asked to approve the document that has been prepared for publication.

Cefndir / Background

Since the 1980s, applications to provide Community Pharmacy services have been assessed by Health Boards and their predecessors, by means of the "control of entry" test. An application to provide pharmacy services is likely to succeed only where a Health Board considers it necessary and expedient to grant it in order to secure adequate pharmacy services within the defined neighbourhood. The under-pinning rationale for introducing a PNA is to ensure the full range of Community Pharmacy services are taken into account and aligned with General Primary Care services and that decisions on the level and extent of Community Pharmacy services are grounded in addressing the identified health care needs of the local population.

The most significant change introduced under the Act relates to the way in which Health Boards make decisions on applications to the Health Board Pharmaceutical List (currently known as Control of Entry). Under the existing 2013 regulations, the location of a pharmacy is dependent upon the contractor deciding to make an application. When Health Boards determine these applications, they are limited to considering need in terms of dispensing services only. No account may be taken of the wider health care needs such as extended opening hours, influenza vaccinations or common ailment services to reduce pressure on GP services and improve patient access to care.

The new PNA regulations change fundamentally how Control of Entry decisions are made by shifting from a system that is driven by the contractors and focused heavily on dispensing, to a system led by the NHS that responds to the wider pharmaceutical needs of local communities. The requirements for a PNA will be aligned with other health needs assessment requirements to support a holistic and comprehensive approach taken to needs assessment. This approach will allow the Health Board to align Community Pharmacy services with its strategic intent of moving services closer to home and supporting our population in their local communities.

The PNA covers the full range of essential, advanced and enhanced services under the Community Pharmacy Contract Framework. This will enable Health Boards to consider the level and extent of pharmaceutical services required to meet the needs of their population, and to do so in the context of their plans and priorities for primary care services and the wider strategic direction of the Health Board.

There are three tiers of community pharmacy services:

- Essential services services which every community pharmacy providing NHS pharmaceutical services must provide. These include the dispensing of medicines, promotion of healthy lifestyles, support for self-care and disposal of unwanted patient medication.
- Advanced services services that all community pharmacy contractors and dispensing appliance contractors can provide subject to specific accreditation and facilities. The current advanced services are Medicines Use Reviews, Discharge Medicines Reviews, Appliance Use Reviews and the Stoma Appliance Customisation Service.
- Enhanced services services that are National (Wales) or which are locally commissioned. These can be offered to all or selected pharmacies, depending on the type of service and the need that it supports. National enhanced services include e.g. the Common Ailments Service, Emergency Contraception, Emergency Supply of Medication, Smoking Cessation and Influenza Vaccination.

Asesiad / Assessment

There are currently 98 NHS pharmacy contracts in Hywel Dda UHB that provide the full range of essential pharmacy services. During the course of compiling the PNA, 1 pharmacy closed, therefore some activity data will relate to 99 rather than 98 pharmacies.

From the 1st October 2021, the Pharmaceutical Needs Assessment will be used by the Health Board when considering whether or not to grant applications to join its pharmaceutical list or dispensing doctor list under The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020. Decisions on such applications may be appealed to Welsh Ministers who will then also refer to the document when hearing any such appeal. It will also be used to inform decisions on applications for the relocation of existing pharmacies and dispensing doctor premises, applications to change pharmacy core opening hours, and the provision of more pharmacy based services to meet local health priorities.

Development of the PNA

The development of the PNA has been overseen by the establishment of the PNA Steering Group. The draft PNA shared for formal consultation was approved by Board on March 25th 2021. The finalised version was submitted and considered at the Strategic Planning and Operational Delivery Committee (SPODC) meeting on 26th August 2021, prior to submission to Board.

Hywel Dda Community Health Council has been fully engaged in the process and raised no concerns with the process followed in the development of the PNA.

As part of the process in preparing this PNA, the views of a wide range of stakeholders, including the public were gathered.

• Public Engagement

A 4-week public engagement exercise was conducted between 12th November and 10th December 2020. An on-line survey was launched, with a paper version also available. 1,370 responses were submitted, which offered an indication of the public's view on current pharmaceutical services available.

• Pharmacy Contractor Questionnaire

Existing pharmacy contractors were asked to complete a questionnaire which asked about facilities available, the need for services not currently available in the area and whether the pharmacy has sufficient capacity to meet an increasing demand for pharmaceutical services. The questionnaire exercise was undertaken in December 2020. All 99 pharmacies completed the questionnaire.

• Dispensing GP Questionnaire

The 6 dispensing GP Practices were invited to provide information via a questionnaire. Information on opening hours, pharmaceutical services and capacity was captured. The practices that are able to dispense to eligible patients, do so over 8 sites

• Draft PNA Consultation

A 60-day consultation on a draft version of the PNA was undertaken from the 7th May to the 6th July 2021. Views were sought from the statutory list of parties to be consulted with together with the wider public. Full details of the responses during the consultation stage can be found at Appendix K in the main PNA documentation attached.

158 responses were received and these were used to update the content of the PNA.

Identifying Gaps

In order to identify whether there are any gaps in the current or future provision of pharmaceutical services within Hywel Dda UHB, a set of criteria was developed to measure the number and location of pharmacies by locality, opening hours and availability of advanced and enhanced services:

- Number of pharmacies per 10,000 population
- Number of pharmacies open within normal working hours (Monday to Friday 9.00am-5.30pm)
- Number of pharmacies open outside normal working hours on weekdays
- Number of pharmacies open on weekends
- Availability of advanced services
- Availability of specific enhanced services

The current and future provision of pharmaceutical services in each of the 7 localities within Hywel Dda UHB were considered against the above criteria.

Conclusion

Full detail of the conclusions can be found in the main PNA documentation attached.

The PNA looks at potential changes during the lifetime of the document. These include projected population growth, housing developments and any future changes in GP opening hours. Given the projected population demographics, housing projects and the distribution of pharmacy services across Carmarthenshire, Pembrokeshire and Ceredigion, the Hywel Dda UHB PNA concludes that:

- The current provision of essential services is sufficient to meet the future needs of the residents during the five-year lifetime of this document.
- The current provision of advanced services is sufficient to meet the future needs of the residents during the five-year lifetime of this document.
- The current provision of enhanced services is sufficient to meet the future needs of the residents during the five-year lifetime of this document. A number of locations have been identified where the provision of certain enhanced services could be improved further, and work will continue with existing pharmacy contactors to promote further uptake of those enhanced services. The Health Board will review uptake of current enhanced services fully in April 2022. Where pharmacies do not take up the offer to provide the identified enhanced services by September 30th 2022, the Health Board will explore the reasons for this and will review the need for additional pharmaceutical services in a particular area.
- No future needs relating to the provision of GP dispensing services have been identified.

There are no gaps in the current provision of services.

Argymhelliad / Recommendation

The Board is asked to note the conclusions reached in this document that indicates no current gaps in service provision and **APPROVE** the Hywel Dda University Pharmaceutical Needs Assessment- October 2021 for publication.

Amcanion: (rhaid cwblhau)	
Objectives: (must be completed)	
Cyfeirnod Cofrestr Risg Datix a Sgôr	1047 Update and publish final Hywel University Health
Cyfredol:	Board Pharmaceutical Needs Assessment
Datix Risk Register Reference and	
Score:	8
Safon(au) Gofal ac lechyd:	1. Staying Healthy
Health and Care Standard(s):	1.1 Health Promotion, Protection and Improvement
Amcanion Strategol y BIP:	2. Working together to be the best we can be
UHB Strategic Objectives:	
Amcanion Llesiant BIP:	4. Improve Population Health through prevention and
UHB Well-being Objectives:	early intervention, supporting people to live happy and
Hyperlink to HDdUHB Well-being	healthy lives
Objectives Annual Report 2018-2019	

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth:	Letters from Director General. Health and Social
Evidence Base:	Services WG (30th April 2018; 23rd May 2019)
	82A of the Public Health (Wales) Act and enacted by
	The National Health Service (Pharmaceutical
	Services)(Wales) Regulations 2020
Rhestr Termau:	PNA - Pharmaceutical Needs Assessment
Glossary of Terms:	
Partïon / Pwyllgorau â ymgynhorwyd	Primary Care Contracts and Senior Pharmacist
ymlaen llaw y Cyfarfod Bwrdd lechyd	Leadership Team
Prifysgol:	PNA Steering Group
Parties / Committees consulted prior to University Health Board:	Hywel Dda Community Health Council

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	There were potential financial risks of funding additional pharmaceutical contracts if gaps in pharmaceutical need were identified. The PNA does not identify any gaps in pharmaceutical need within the Health Board.

Ansawdd / Gofal Claf: Quality / Patient Care:	The new PNA regulations will change fundamentally how the Community Pharmacy Control of Entry decisions are made, by shifting from a system that is driven by the contractors and focused heavily on dispensing, to a system led by the NHS that responds to the wider pharmaceutical needs of local communities. This approach should improve access to care, widen the enhanced services provided by community pharmacies and support the inverse care principles of targeting health care provision where there is the greatest need.
Gweithlu: Workforce:	N/A
Risg: Risk:	There is a risk of non-compliance to the legal requirement set out in section 82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020, to publish a Pharmaceutical Needs Assessment (PNA) by 1 st October 2021. RR Reference: 1047 (After mitigation score 4)
Cyfreithiol: Legal:	82A of the Public Health (Wales) Act and enacted by The National Health Service (Pharmaceutical Services) (Wales) Regulations 2020.
Enw Da: Reputational:	Legal requirement to complete and publish by October 2021
Gyfrinachedd: Privacy:	N/A
Cydraddoldeb: Equality:	The PNA incorporates the provision of the Equality Act 2010 to ensure that the assessment of pharmaceutical need considers the protected characteristics under the Act.